CV benefits of rosuvastatin, compared with placebo, are sustained or enhanced even after stopping therapy in individuals without CVD but at intermediate risk for CV events.

Prof. Stephen Nicholls discusses the results of a study that investigated the lipid-lowering effects of triple therapy with bempedoic acid, ezetimibe and statin as a new potential strategy for treating hypercholesterolemia.

Elevated levels of apoB and non-HDL-c better reflect residual risk for all-cause mortality and MI than LDL-c levels in patients treated with statins.

The prospective BIOSIGNAL cohort study showed that elevated Lp(a) was independently associated with LAA stroke etiology and risk of recurrent AIS or TIA in patients <60 years.

This study investigated the risk of incident CAD in participants from the UK Biobank with and without a family history of CVD in a sibling or parent.

This phase 2 randomized clinical trial showed that initiation of triple therapy with statin, ezetimibe and bempedoic acid significantly reduced LDL-c by 60.5%, compared with placebo.

This study in a large, contemporary general population cohort showed that low and high LDL-c levels are associated with all cause mortality. LDL-c of 3.6 mmol/L (140 mg/dL) was associated with the lowest risk of all cause mortality.

Large-scale observational data from the SWEDEHEART registry showed that in patients in clinical practice early and aggressive LDL-c lowering after MI was associated with reduced risk of major CV outcomes and mortality.

In a contemporary primary prevention cohort, MI and ASCVD event rates increased with higher LDL-c and older age. NNT to prevent one MI or ASCVD event was lower in people aged 70-100 years compared to younger individuals.

A study using data from the Copenhagen General Population Study showed that cholesterol in VLDL explains 50% of the MI risk from apoB-containing lipoproteins. Triglycerides in VLDL explain 0%. With poll.

This educational program consists of three presentations on residual CVD risk with a focus on triglycerides and triglyceride-rich lipoproteins.

The DA VINCI study demonstrated that the majority of prescibed therapies for lipid-lowering in Europe is monotherapy with statins and only one-third of patients met their LDL-c goal described in the 2019 dyslipidemia guidelines. With poll.